| Market revenue in 2024 | USD 32.6 million |
| Market revenue in 2030 | USD 98.7 million |
| Growth rate | 20.4% (CAGR from 2025 to 2030) |
| Largest segment | Services |
| Fastest growing segment | Services |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Services, NGS Commercial Software |
| Key market players worldwide | Bio-Rad Laboratories Inc, DNAnexus, Qiagen NV, DNAstar, Pacific Biosciences of California Inc, Eurofins Scientific SE, Illumina Inc, PierianDx, Agilent Technologies Inc, Roche Holding AG, Alphabet Inc Class A, Thermo Fisher Scientific Inc, Golden Helix, Scigenom Labs, Genuity Science, Fabric Genomics (formerly Omicia), Congenica, Precigen |
Canada NGS data analysis market is expected to grow at a significant rate with a number of provincial and national initiatives undertaken for NGS-based research. For instance, Exactis Innovation, a nonprofit, pan-Canadian organization, offers accelerated access to clinical trials for personalized medicine, especially for cancer.
The Personalize My Treatment program of Exactis focuses on the selection of patients suitable for clinical trials based on sequencing studies. Such initiatives drive the demand for NGS-based software in these clinical trials in Canada. Furthermore, several initiatives are being undertaken by key players, such as Qiagen, Illumina, Roche, and Thermo Fisher Scientific, Inc., present in the country.
Government agencies are also involved in such activities to broaden the landscape of NGS technologies in Canada, which further drives market growth. For instance, in July 2019, the Ontario Institute for Cancer Research, Genome Canada, and Thermo Fisher Scientific, Inc. collaborated for the development of a complete solution of targeted NGS assays & analysis software.
Publish Date: Nov 10, 2025
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Alphabet Inc Class A | View profile | 180,895 | 1600 Amphitheatre Parkway, Mountain View, CA, United States, 94043 | www.abc.xyz |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
| Pacific Biosciences of California Inc | View profile | 796 | 1305 O’Brien Drive, Menlo Park, CA, United States, 94025 | www.pacb.com |
| DNAnexus | View profile | 101-250 | Mountain View, California, United States, North America | dnanexus.com |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Next-generation Sequencing Data Analysis Market Outlook will help companies and investors design strategic landscapes.
Services was the largest segment with a revenue share of 64.72% in 2024.
Horizon Databook has segmented the Canada next-generation sequencing data analysis market based on services, ngs commercial software covering the revenue growth of each sub-segment from 2018 to 2030.
Canada NGS data analysis market is expected to grow at a significant rate with a number of provincial and national initiatives undertaken for NGS-based research. For instance, Exactis Innovation, a nonprofit, pan-Canadian organization, offers accelerated access to clinical trials for personalized medicine, especially for cancer.
The Personalize My Treatment program of Exactis focuses on the selection of patients suitable for clinical trials based on sequencing studies. Such initiatives drive the demand for NGS-based software in these clinical trials in Canada. Furthermore, several initiatives are being undertaken by key players, such as Qiagen, Illumina, Roche, and Thermo Fisher Scientific, Inc., present in the country.
Government agencies are also involved in such activities to broaden the landscape of NGS technologies in Canada, which further drives market growth. For instance, in July 2019, the Ontario Institute for Cancer Research, Genome Canada, and Thermo Fisher Scientific, Inc. collaborated for the development of a complete solution of targeted NGS assays & analysis software.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Next-generation Sequencing Data Analysis Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Next-generation Sequencing Data Analysis Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
